Bronchial Diseases
11
1
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
9.1%
1 terminated out of 11 trials
85.7%
-0.8% vs benchmark
27%
3 trials in Phase 3/4
67%
4 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Cross-sectional Characterization of Idiopathic Bronchiectasis
Individualizing Treatment for Asthma in Primary Care
Patient Reported Outcome and Experience Measures for Bronchoscopic Procedures
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Anti-viral Effects of Azithromycin in Patients With Asthma and COPD
Asthma Data Innovation Demonstration Project
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects
Greatest International Antiinfective Trial With Avelox
Effect of PUR003 on Asthma